NovoCure (FRA:038) 3-Year Revenue Growth Rate : 2.80% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure 3-Year Revenue Growth Rate?

NovoCure's Revenue per Share for the three months ended in Dec. 2024 was €1.42.

During the past 12 months, NovoCure's average Revenue per Share Growth Rate was 17.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 31.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of NovoCure was 110.30% per year. The lowest was 1.80% per year. And the median was 31.50% per year.

Competitive Comparison of NovoCure's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, NovoCure's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where NovoCure's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

NovoCure 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

NovoCure (FRA:038) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

NovoCure 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of NovoCure's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

NVCR:USA 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines